Key Highlights

  • Shares were quoted at 10.56 GBX on 26 August 2026, a decline of 6.18%.
  • The company provides antibody engineering and discovery services to biopharmaceutical clients.
  • Service offerings span humanisation, optimisation and expression work.
  • Demand is linked to research budgets across the biopharmaceutical development sector.

Fusion Antibodies Plc (LSE:FAB) was quoted at 10.56 GBX on 26 August 2026, a decline of 6.18% on the session. The movement placed the company among the softer performers across the London market during the day's trading.

Business Overview

Fusion Antibodies Plc provides specialist services to organisations developing antibody-based therapeutics. The company works on contract for biopharmaceutical clients, undertaking the technical work involved in discovering, engineering and characterising antibody candidates.

Service capabilities have historically included humanisation, which adapts antibodies derived from animal sources so they are better tolerated in human patients, alongside affinity optimisation, expression and stability work. These are specialised technical disciplines that many developers prefer to outsource rather than build internally, particularly where the requirement is project-based.

Share Price Movement

On 26 August 2026, shares in LSE:FAB were quoted at 10.56 GBX, a decline of 6.18% on the session. The move positioned the company among the softer performers across the London market during the day's trading.

Companies of this size operating in specialised life sciences services frequently see share price movements of this order, reflecting limited trading Liquidity alongside sensitivity to contract newsflow and funding conditions in the client base.

Market Backdrop

Demand for outsourced antibody services follows Research and Development activity across the biopharmaceutical development landscape. When funding conditions for smaller developers are supportive, project volumes tend to build; when Capital becomes harder to raise, discretionary programmes are often deferred or scaled back.

Antibody-based therapeutics remain a substantial area of pharmaceutical development, spanning oncology, immunology and infectious disease applications. The underlying scientific momentum provides a structural backdrop, though the translation into service Demand depends on the funding environment facing developers.

Risk Considerations

Revenue visibility can be limited where work is project-based, with contract timing influencing period-to-period comparisons. Client concentration may also feature, given that individual projects can represent meaningful proportions of activity.

Companies at this scale carry the operational challenge of matching a specialised technical cost base to variable project volumes. Competition comes from a range of contract research organisations, including larger providers offering integrated service packages.

Outlook

The picture for Fusion Antibodies rests principally on contract flow, the funding environment facing biopharmaceutical developers and the company's ability to convert its technical capabilities into repeat relationships.

For those tracking LSE:FAB, order intake and the balance between the technical cost base and project volumes remain the operational markers of greatest relevance.